Nagasaki University;Iwate Medical University;Japanese Foundation For Cancer Research
发明人:
申请号：
EP18776029.3
公开号：
EP3604312A1
申请日:
2018.03.29
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.A compound represented by the formula (I):whereinX is O or NH,R1 and R2 are each independently a hydrogen atom or an optionally substituted hydrocarbon group；R3 and R4 are each independently a hydrogen atom, a halogen atom or an optionally substituted hydrocarbon group, andR5 and R6 are each independently an optionally substituted hydrocarbon group, excluding the following compounds: or a salt thereof.
